This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macinga, D. R.
Right arrow Articles by Morris, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macinga, D. R.
Right arrow Articles by Morris, T. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2526-2537, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2526-2537.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Unique Biological Properties and Molecular Mechanism of 5,6-Bridged Quinolones

David R. Macinga,{dagger} Paul J. Renick ,{ddagger} Kelly M. Makin, David H. Ellis, Allison A. Kreiner, Min Li, Kirk J. Rupnik, Erica M. Kincaid,§ Cynthia D. Wallace, Benoit Ledoussal, and Timothy W. Morris{dagger}*

Procter & Gamble Pharmaceuticals, Mason, Ohio 45040

Received 14 January 2003/ Returned for modification 26 February 2003/ Accepted 2 May 2003

We have characterized an early series of 5,6-bridged dioxinoquinolones which behaved strikingly different from typical quinolones. The 5,6-bridged dioxinoquinolones inhibited Escherichia coli DNA gyrase supercoiling activity but, unlike typical quinolones, failed to stimulate gyrase-dependent cleavable complex formation. Analogous unsubstituted compounds stimulated cleavable complex formation but were considerably less potent than the corresponding 5,6-bridged compounds. Consistent with a previous report (M. Antoine et al., Chim. Ther. 7:434-443, 1972) and contrary to established quinolone SAR trends, a compound with an N-1 methyl substitution (PGE-8367769) was more potent than its analog with an N-1 ethyl substitution (PGE-6596491). PGE-8367769 was shown to antagonize ciprofloxacin-mediated cleavable complex formation in a dose-dependent manner, suggesting an interaction with the gyrase-DNA complex that overlaps that of ciprofloxacin. Resistance to PGE-8367769 in E. coli was found to arise through missense mutations in gyrA, implicating DNA gyrase as the primary antibacterial target. Notably, only 1 of 15 distinct mutations selected on PGE-8367769 (D87G) has previously been implicated in quinolone resistance in E. coli. The remaining 14 mutations (E16V, G31V, R38L, G40A, Y50D, V70A, A84V, I89L, M135T, G173S, T180I, F217C, P218T, and F513C) have not been previously reported, and most were located outside of the traditional quinolone resistance-determining region. These novel GyrA mutations decreased sensitivity to 5,6-bridged dioxinoquinolones by four- to eightfold, whereas they did not confer resistance to other quinolones such as ciprofloxacin, clinafloxacin, or nalidixic acid. These results demonstrate that the 5,6-bridged quinolones act via a mechanism that is related to but qualitatively different from that of typical quinolones.

* Corresponding author. Present address: Cumbre, Inc., 1502 Viceroy Drive, Dallas, TX 75235. Phone: (214) 631-4700. Fax: (214) 631-4710. E-mail: tim.morris{at}cumbre.biz.

{dagger} Present address: GOJO Industries, Akron, Ohio.

{ddagger} Present address: Cumbre, Inc., Dallas, Tex.

§ Present address: Division of Experimental Hematology, Cincinnati Children's Hospital, Cincinnati, Ohio.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2526-2537, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2526-2537.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Flatman, R. H., Howells, A. J., Heide, L., Fiedler, H.-P., Maxwell, A. (2005). Simocyclinone D8, an Inhibitor of DNA Gyrase with a Novel Mode of Action. Antimicrob. Agents Chemother. 49: 1093-1100 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»